title: Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice.
abstract: In this study, simvastatin (SMV) and SMV nanoliposome (SMV-Lipo) were given to male BALB/c mice by either intragastric (i.g.) or intraperitoneal (i.p.) administration, and their effects on isoproterenol (ISO)-induced cardiac remodeling were compared. The results indicate that by i.p. administration, the SMV-Lipo at an equal SMV dose exhibited more significant inhibitory effects than the crude SMV on cardiac hypertrophy, fibrosis and inflammation. Comparing the SMV-Lipo on different administration regimens, i.p. group showed more significant inhibitory effects on cardiac remodeling than i.g. group. In addition, pharmacokinetic studies revealed that SMV-Lipo administrated by either i.p. or i.g. more significantly improved the plasma SMV concentration than the crude SMV. Therefore, the SMV-Lipo significantly enhanced the inhibitory effects of SMV on cardiac remodeling resulted from the enhanced absorption of SMV by nanoliposome formulation, and i.p. was better than i.g. administration.
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Peking University, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China; School of Basic Medical Science, Shihezi University, Shihezi, Xinjiang, China.
authors.forename: Nuerbiye
authors.initials: N
authors.lastname: Tuerdi
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Peking University, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Xu
authors.affiliation: Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China.
authors.forename: Baoling
authors.initials: B
authors.lastname: Zhu
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Peking University, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Chen
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Peking University, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China.
authors.forename: Yini
authors.initials: Y
authors.lastname: Cao
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Peking University, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China.
authors.forename: Yunan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: School of Pharmaceutical Sciences, Peking University, Beijing, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China. Electronic address: lzjgy1995@163.com.
authors.forename: Zijian
authors.initials: Z
authors.lastname: Li
authors.affiliation: Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, Peking University, Beijing, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing, China; School of Basic Medical Science, Shihezi University, Shihezi, Xinjiang, China. Electronic address: ronaqi@bjmu.edu.cn.
authors.forename: Rong
authors.initials: R
authors.lastname: Qi
mesh_terms: D000818:Animals; D064752:Atrial Remodeling; D005355:Fibrosis; D006321:Heart; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007545:Isoproterenol; D008081:Liposomes; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles; D019821:Simvastatin / Q000494:pharmacology*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008081:Liposomes; D019821:Simvastatin; D007545:Isoproterenol
keywords: Bioavailability; Cardiac remodeling; Isoproterenol; Nanoliposome; Simvastatin